<SEC-DOCUMENT>0001213900-21-006314.txt : 20210203
<SEC-HEADER>0001213900-21-006314.hdr.sgml : 20210203
<ACCEPTANCE-DATETIME>20210203075530
ACCESSION NUMBER:		0001213900-21-006314
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210203
FILED AS OF DATE:		20210203
DATE AS OF CHANGE:		20210203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		21584223

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea134460-6k_enlivex.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the month of: February 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name into
English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 3, 2021, Enlivex Therapeutics Ltd.,
a company organized under the laws of the State of Israel, issued a press release announcing positive top-line results from a multi-center,
investigator-initiated Phase II clinical trial evaluating Allocetra&trade; in severe and critical COVID-19 patients. A copy of
such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U><A HREF="ea134460ex99-1_enlivex.htm" STYLE="-sec-extract: exhibit">Press Release issued by Enlivex Therapeutics Ltd. on February 3, 2021.</A></U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: February 3, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea134460ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="image_001.jpg" ALT="Logo, company name&#10;&#10;Description automatically generated" STYLE="height: 113px; width: 182px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0">Enlivex Reports Positive Top-Line Results from Phase II Clinical
Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Phase II (16 patients treated, 9/16 (56%) with severe illness,
7/16 (44%) with critical illness, follow-up period of 28 days post-Allocetra<SUP>TM</SUP> treatment)</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>0/16 (0%) mortality on day-28</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>14/16 (87.5%) patients recovered and were discharged from the hospital by day-28</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>Average duration of hospitalization post administration of Allocetra<SUP>TM</SUP> for discharged patients was 5.3 days </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>2/16 (12.5%) patients, both of whom had critical illness at the time of Allocetra<SUP>TM</SUP> treatment, were hospitalized
in the ICU on a respirator on day-28</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Phase II + Ib (21 patients treated, 11/21 (52%) with severe illness,
10/21 (48%) with critical illness)</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>0/21 (0%) mortality on day-28 </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>19/21 (90.5%) patients recovered and were discharged from the hospital by day-28</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>Average duration of hospitalization post administration of Allocetra<SUP>TM</SUP> for discharged patients was 5.6 days </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>2/21 (9.5%) patients, both of whom had critical illness at the time of Allocetra<SUP>TM</SUP> treatment, were hospitalized
in the ICU on a respirator on day-28</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Based on the positive safety and efficacy results from the Phase
II trial and in consultation with the trial&rsquo;s principal investigator, the Company has completed the Phase II trial early
after enrolling sixteen, rather than twenty-four, patients. The Company expects to submit a summary of the data to regulatory bodies
later this month to serve as the basis for a discussion on the next steps in Allocetra&rsquo;s regulatory pathway in COVID-19 patients
with severe or critical illness. </B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Allocetra&rsquo;s
intrinsic mechanism of action is immune-modulation, and is expected to potentially be relevant to COVID-19 severe/critical patients
infected by various coronavirus strain mutations</B></FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nes Ziona, Israel, February 3, 2021 (GLOBE NEWSWIRE) --&nbsp;</B>Enlivex
Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming immunotherapy company targeting
diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today reported positive top-line results from a multi-center,
investigator-initiated Phase II clinical trial evaluating Allocetra<SUP>TM</SUP> in severe and critical COVID-19 patients. Based
on the positive results and in consultation with the trial&rsquo;s principal investigator, the Company has completed the trial
early and plans to submit a summary of the data for review by the relevant regulatory bodies. Submission of the data summary to
regulators is expected later this month and will serve as the basis for a discussion with regulators on the next steps in Allocetra&rsquo;s
regulatory pathway in COVID-19 patients with severe or critical illness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sixteen COVID-19 patients were treated with Allocetra<SUP>TM</SUP>
in the Phase II clinical trial, which originally was expected to enroll twenty-four patients. The clinical trial was completed
early in support of anticipated accelerated regulatory filings of the trial&rsquo;s positive safety and efficacy data. Of the sixteen
patients enrolled in the Phase II trial, nine (9/16, 56%) were in severe condition and seven (7/16, 44%) were in critical condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key results and conclusions from both the Phase II clinical
trial, as well as a previously reported investigator-initiated Phase Ib study of Allocetra<SUP>TM </SUP>in severe and critical
COVID-19 patients, include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourteen of sixteen (87.5%) Phase II trial patients
had recovery from their respective severe/critical condition and were discharged from the hospital after an average of 5.3 days
following Allocetra<SUP>TM </SUP>administration (average of 4.2 days for severe patients and 7.2 days for critical patients).</FONT><BR>
</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Nineteen of twenty one (90.5%) Phase II and Phase Ib trial patients,
in the aggregate, had recovery from their respective severe/critical condition and were discharged from the hospital after an average
of 5.6 days following Allocetra<SUP>TM </SUP>administration (average of 4.1 days for severe patients and 7.7 days for critical
patients).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The mortality rate at 28 days (day-28 post-Allocetra<SUP>TM</SUP>
treatment was the end of the trial&rsquo;s follow-up period) for participants in the Phase II trial was 0% (0/16). The same 0%
(0/21) mortality rate was observed in an aggregate analysis of all patients treated in the Phase Ib and Phase II studies. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Majority of the patients treated in the Phase Ib and Phase II studies
had pre-existing risk factors such as male gender, obesity and hypertension </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data from the investigator-initiated Phase II trial, as well
as an audited analysis of the Phase Ib trial are shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Trial</FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"># Patients enrolled</FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disease Severity</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Outcome</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Hospitalization</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Discharged patients, post Administration of
        Allocetra<SUP>TM</SUP></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Recovered</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Day 28</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Mortality</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Day 28</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Discharged</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Day 28</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duration <BR>
(days, avg.)</FONT></TD></TR>
<TR>
    <TD STYLE="width: 11%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase Ib</FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD>
    <TD STYLE="vertical-align: top; width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2 Severe</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">3 Critical</P></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/5 (100%)</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0/5 (0%)</FONT></TD>
    <TD STYLE="width: 21%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/5 (100%)</FONT></TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase II</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">9 Severe</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">7 Critical</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/16 (87.5%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0/16 (0%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/16 (87.5%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">11 Severe</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">10 Critical</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19/21 (90.5%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0/21 (0%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19/21 (90.5%)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prof. Vernon van Heerden, Head of the General Intensive
Care Unit at Hadassah Medical Center in Israel and the lead investigator of both the prior Phase Ib and the now-completed
Phase II clinical trials of Allocetra<SUP>TM</SUP> in severe and critical COVID-19 patients stated, &ldquo;The results we
have seen from the twenty-one COVID-19 patients treated to date with Allocetra<SUP>TM </SUP>are exciting. The Phase II
patients who have been discharged from the hospital are currently healthy. We believe that these compelling results have
demonstrated the safety and efficacy of Allocetra<SUP>TM</SUP>&nbsp;in these complicated patients, highlighting the potential
of Enlivex&rsquo;s product candidate to benefit severe and critical COVID-19 patients as well as others suffering from
cytokine storms and organ dysfunctions across various clinical indications.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prof. Dror Mevorach, M.D., Chief Scientific and Medical Officer
of Enlivex, added, &ldquo;We believe the results from the COVID-19 clinical trials of Allocetra<SUP>TM</SUP> represent a unique
opportunity for severe and critical COVID-19 patients, on top of standard of care. The data suggest that Allocetra<SUP>TM</SUP>&nbsp;may
have utility as a safe and efficacious treatment for reprogramming macrophages and resolving states of organ failures both in this
COVID-19 patient population, regardless of the specific coronavirus mutation that inflicted
the patients, and across different life-threatening, high mortality clinical indications with high unmet medical
needs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex
commented, &ldquo;We are pleased with the top-line results of this Phase II clinical trial. We believe that Allocetra<SUP>TM</SUP>,
if approved, could potentially cover the void that currently exists for the treatment of severe and critical COVID-19 patients.
COVID-19 vaccines are game-changers in the fight against the pandemic, yet with various surveys demonstrating 25-32% of the population
in the United States and major European countries unwilling to get vaccinated<SUP>1</SUP>, and concerns surrounding various mutant
strains of the SARS-CoV-2 virus, our commercial model estimates continued demand for the treatment of severe and critical COVID-19
patients for years to come.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT THE ALLOCETRA COVID-19 PHASE II CLINICAL TRIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The COVID-19 study is a multi-center, investigator-initiated,
Phase II clinical trial. The trial was designed to recruit up to twenty-four COVID-19 patients in severe or critical condition,
as defined by the U.S. National Institute of Health (NIH), in order to assess Allocetra<SUP>TM</SUP> in combination with standard
of care treatment. Safety, tolerability, cytokine profile and efficacy parameters are planned to be evaluated. Up to twenty-four
patients were expected to be recruited, subject to each patient&rsquo;s eligibility and signing of an informed consent to participate
and receive treatment. However, due to a positive safety and efficacy top-line analysis of the results from the first sixteen (16)
patients, the study is now completed and closed and will not recruit additional patients. Twelve (12) patients were recruited at
Hadassah Medical Center, three (3) patients at Barzilai Medical Center, and one (1) patient at Ziv Medical Center. Eligibility
criteria included an existing illness with at least one of (a) radiographic infiltrates by imaging (chest x-ray, CT scan, etc.),
or (b) Sp/O<SUB>2</SUB> ratio lower than or equal to 93% on room air, or (c) requiring supplemental oxygen (low flow or high flow),
with a P/F ratio of below 350 but higher than 150. Exclusion criteria included (a) pregnancy, lactation and childbearing potential
woman who are not willing to use acceptable contraceptives measures for the entire study duration, (b) illness combined with other
organ failure requiring organ support other than a respirator, including Stage 4 severe chronic kidney disease or requiring dialysis
(i.e. estimated glomerular filtration rate (eGFR) &lt; 30), (c) intubated patients (due to inability to sign an informed consent),
(d) patients with malignant tumor, other serious systemic diseases and psychosis, (e) patients who are participating in other clinical
trials or treated with any experimental agents that may contradict this trial, (f) co-infection of HIV or tuberculosis, (g) known
immunocompromised state or medications known to be immunosuppressive, and (h) patients with P/F ratio or S/F ratio of &lt;150 or
a change in status of eligibility manifested by a rapid decline of P/F ratio between eligibility status and actual drug delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ALLOCETRA<SUP>TM</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Allocetra<SUP>TM</SUP> is a universal,
off-the-shelf cell therapy designed to&nbsp;reprogram macrophages into their homeostatic state. Diseases such as solid cancers,
sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute
significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra<SUP>TM</SUP> has the potential
to provide a novel immunotherapeutic mechanism of action&nbsp;for life-threatening clinical indications that are defined as &ldquo;unmet
medical needs&rdquo;, as a stand-alone therapy or in combination with leading therapeutic agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><SUP>1</SUP> Nature: A global survey
of potential acceptance of a COVID-19 vaccine, Oct 20, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>ABOUT ENLIVEX</B><BR>
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra<SUP>TM</SUP>, a universal, off-the-shelf
cell therapy designed to&nbsp;reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their
homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information,
visit&nbsp;http://www.enlivex.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Safe Harbor Statement:&nbsp; This press release contains
forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo;,
&ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo;
and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results
of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs.
All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex&rsquo;s
business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial
products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate
data that would support the approval or marketing of these products for the indications being studied or for other indications;
that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results
to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce
results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may
differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product
line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.&nbsp;
In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological
and other factors discussed in Enlivex&rsquo;s filings with the Securities and Exchange Commission, including in the Company&rsquo;s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements
contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update
forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ENLIVEX CONTACT<BR>
</B>Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR RELATIONS CONTACT</B><BR>
Eric Ribner<BR>
LifeSci Advisors<BR>
eric@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !Q +8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
